

FOR IMMEDIATE RELEASE

ZODIAC REPORTS PROGRESS

Sydney, – February 2, 2009 - Zodiac Capital Limited – an investment group publicly listed on the NSX in Australia ("ZOD") advises that whilst the Company is well positioned with its major project assets, the Company advises that it has needed to curtail the provision of loan capital to its various undertakings and to take steps to cut overheads in order to tackle the prevailing market conditions.

Currently Zodiac Capital has provided loan capital of over \$1,800,000 to its major assets under development and is dependent upon the realisation of these, either through public listings, mergers, joint venture or sale in order to be able to realise the substantive asset values and to be repaid its loan capital.

The Company advises that it is in negotiation and discussion regarding the commercial realisation of each of its four major project assets and is seeking to achieve realisation and resolution of its affairs within the next 90 days.

We provide herewith an Overview of the Company and its current major project assets for the information of the Market and our Shareholders and the Company will advise of any progress as it materialises.

For all inquiries please contact:

Peter Squire +61 (0) 400 025 471 peter.squire@zodiaccap.com

Zodiac Capital Limited
Level 1, 275 George Street
Sydney NSW 2000
Tel: +61 (0) 2 9299 9270

Corporate Profile


Zodiac Capital Limited is a boutique investment group publicly listed on the National Stock Exchange of Australia (NSX). Zodiac focuses on special situation business and investment opportunities that are generally suited to public listing or purchase by or merger with a public company. Following project identification, Zodiac invests and arranges funds, builds expert teams, and realizes growth in capital value of its holdings through public offerings or alternate divestitures.

Zodiac's project investment activities are focused on the creation, syndication and management of investment projects for itself – as a principal, its shareholders and for its syndication and/or investor partners. Syndication and investor partners in any specific project may include wholesale investors such as Australian and multi-national institutions and high net worth individuals as well as retail investors introduced to publicly listed interests through Zodiac appointed licensed retail distribution partners.

Current Major Project Assets include:

Consolidated Iron Sands

Zodiac Capital has a controlling interest in Consolidated Iron Sands Limited (CIS). CIS plans to list on the Australian Stock Exchange (ASX) in the first half of 2009. CIS owns key iron sands tenements over 16,300 hectares (163 square kilometres) within the shallow offshore regions of the northern Philippines coastline. Extensive magnetite sand reserves were identified within the immediate region through studies spanning the period 1970-1990 by the Philippine Mines and Geosciences Bureau and by a United Nations Exploration Survey program. A ban on offshore mining has recently been lifted, providing CIS the opportunity to contribute to the re-establishment of the Philippines as a strategic and significant supplier of iron ore on a world scale. Following public listing CIS is planning initial iron ore magnetite fines production of 2 million tones per annum commencing in late 2010.



- Iron Ore
- Close to China, Japan and Korea
- Significant potential reserves
- Low cost production

Dynamic Agricultural Products Ltd.

Zodiac Capital owns a majority and controlling interest in Dynamic Agricultural Products Limited which plans to list on the Australian Stock Exchange (ASX) in the course of 2009. Dynamic is commercializing, GroWall, a patent pending system, which incorporates proven technologies that address bio-security, water quality and availability, availability of arable land and the control of pests, mould and other bacterial problems that often threaten traditional and intensive production methods. The Dynamic GroWall system introduces vertical automated farming that can be sited in any location ranging from remote sites in developing countries to city warehouses. This provides dramatic and cost-effective reduction in carbon emissions, water usage, spoilage losses, fertilizers, pesticides, refrigeration, land use and freight. It can - naturally and organically - produce vegetables and other crops at up to seven times the growth rate of traditional methods. Comparatively, each 10,000 square metre unit can replace up to 50,000 acres of traditional production land and use only 1000th of the water and no pesticides or herbicides.



- Agricultural
- Grows organic food almost anywhere
- Year round production
- Fraction of water and land requirements
- Carbon Credit positive

Zocap Pharma

Zocap Pharma owns the global rights to 26 fully developed phyto-pharmaceutical products, including a number of potential blockbuster candidates that have been developed within Russian research institutes over the past 25 years and are currently only available through pharmacies in the Ukraine. The products have many of the attributes of true pharmaceuticals and are regulated in most countries under such categories as natural remedies, food supplements or traditional medicines. Zocap has started operations that will lead to early marketing initiatives in selected regions and looks forward to achieving potentially significant revenues within its first full year of operations as these markets expand and the Zocap products are introduced to new regions. The first Zocap Pharma brand product that the Company is focused on introducing to global markets is Immunoxel, a proven and very effective complementary agent in the treatment of tuberculosis ("TB"), a highly contagious condition and major scourge within mainly developing countries and a serious health threat to the western world. Approximately a third of the world's population now carries the TB bacteria. Extensive clinical trials show that Immunoxel significantly enhances the effects of anti-TB and anti-TB/HIV drugs and protects the liver from drug related toxicity. Importantly, Immunoxel has demonstrated significant effectiveness against the rapidly emerging drug resistant strains of TB. Other key Zocap products in clinical trials have demonstrated effectiveness in the reduction of cholesterol (Cholonorm) and blood sugar (Diabetin).

ZOCAP PHARMA

- Phyto-pharmaceutical all natural
- Existing product range of 26+
- Global rights
- Effective in treating significant conditions – TB, HIV, cholesterol, diabetes

Royal Silk Racing Limited

Zodiac Capital owns a controlling and majority interest in Royal Silk Racing Limited (RSR) which is planning to list on the National Stock Exchange of Australia (NSX) in early 2009. RSR has combined an internet portal business to be centred around the Japanese language version (ギャンブル) of gambling.com with horse racing: owning and leasing thoroughbreds for racing throughout Australia. Through the Japanese gaming and gambling portal, RSR aims, over the next several years, aims to realise a stable and profitable revenue base that will provide a financial anchor for RSR's early and continued success. RSR's thoroughbred operations are conducted through a wholly owned subsidiary, Thoroughbred City Pty Ltd and includes a training base at Moruya, NSW headed by an exciting young trainer, Ms. Colbey Hill, who is already producing exceptional results in her first year of thoroughbred training.



- Gaming in Japan and Thoroughbreds in Australia
- Ownership of horses
- Unique Japanese domain

Zodiac Capital Team

Directors

Robin Armstrong – *Non Executive Chairman* – is a Sydney based stockbroker and has vast and successful experience in advisory, corporate structuring and financings and serves as a non executive director on a number of public companies.

Peter Boonen – *Managing Director* – the Company's founder has over 30 years of extensive experience in the business, property, investment banking and global equity markets. Mr. Boonen is responsible for the Company's management, corporate development strategy and for the identification and negotiation of investment and transaction candidates.

Don Bénard – *Executive Director* – is a Senior Geologist and Mining Engineer with over 20 years extensive global resource industry experience in Canada, USA, China and the Asia Pacific region.

Dr. Allen Bain – *Non executive Director* – has held leadership roles in both the business sector and in the science of drug discovery and commercialisation. He has been a co-founder, officer, or director of several public companies including Cardiome Pharma (NASDAQ:CRME), whose flagship cardiac drug has recently completed Phase III clinical trials in the U.S.

Senior Management and Key Consultants

Gulshan Jugroo – *CFO and Company Secretary* – has an Accounting degree from Middlesex University, UK and a Masters of Business (corporate forensic accounting specialization) from Victoria University.

Colin Bloomfield – *Company Secretary* – a member of the Institute of Chartered Accountants since 1979 and a Fellow of the Institute since 1990. He specializes in corporate, general management, tax planning, and has served as a director and/or company secretary of several listed companies.

Prishani Bhurtun – *Accountant and Office Manager* – highly qualified with Masters in both Accounting and Marketing and a Diploma in International Trade. She has experience in international and domestic marketing, strategic planning, implementation and business development.

Brian Bisset – *IT Adviser* – an Information Technology specialist, Brian has worked for over 20 years in IT/systems consulting with many financial services companies – especially those involved in communications, investor relations, strategic management services, and investment banking.

Peter Squire – *Manager Corporate / Institutional* – works as Project Manager, leads IR, creates and implements sales and growth strategies at Zodiac and its business units. He has worked across a wide range of roles in the finance sector including Product Development, Marketing, Sales, General Management, Alliances & Partnering and Business Consulting.

Chris Webb – *CEO Consolidated Iron Sands Limited* – has over 20 years experience in over 15 developing and transitional Asian countries in contracted senior executive positions, with both private and public sector involvement in project design, management, implementation, and business plan development and start-up.

Daniel Lasher – *Philippine Office Manager and Liaison Officer* – (Manila) is fluent in the Tagalog language as well as the Southern Philippine Dialect. He is an ex-marine formerly attached to the US Embassy in Manila and has well established relationships within the Philippines government and business community.

David Hsieh – *China Liaison Officer* – (Beijing) has extensive Asia-Pacific government, industry and media contacts and relationships, and his extensive business experience includes business development and international financing for exploration, mining, and mineral processing projects.

Dr. Aldar S. Bourinbaier – *Consultant Pharmacologist and Patent and IP Advisor* – has over 25 years experience in academia, biotech and patent law and has a PhD in genetics from the University of Paris where he graduated with an Immunology/Oncology specialization. He is well published and his work laid the basis for the reference standard used in all commercial HIV PCR kits sold worldwide. He was also first to discover the new class of non-peptide, coumarin-type HIV protease inhibitor drugs, of which the first drug in this class, tipranavir (Boehringer Ingelheim), was approved by the FDA

Dr. John Watling – *Consultant Geochemist, Metallurgical Specialist and Geologist* – provides specialist consulting services to the Company and is regarded among the world's leading forensic scientists specialising in geochemistry, analytical chemistry, environmental and mineral chemistry.

Dr. Bryce Wood – *Mining Engineering Consultant* – has worked on mineral deposits all around the world, including diamond, gold, platinum, copper, nickel, lead, zinc and iron mining operations. He provides advice on technical and valuation matters relating to geological, mining and metallurgical interests.